Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis

Jennifer S Guimbellot; David P Nichols; John J Brewington

doi:10.1016/j.ccm.2022.06.005

Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis

Clin Chest Med. 2022 Dec;43(4):617-630. doi: 10.1016/j.ccm.2022.06.005.

Authors

Jennifer S Guimbellot¹, David P Nichols², John J Brewington³

Affiliations

¹ Department of Pediatrics, Division of Pulmonary and Sleep Medicine, Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham; 1600 7th Avenue South, ACC 620, Birmingham, AL 35233, USA.
² Department of Pediatrics, Division of Pulmonary Medicine, Seattle Children's Hospital, University of Washington School of Medicine, Building Cure, 1920 Terry Avenue, Office 4-209, Seattle, WA 98109, USA.
³ Department of Pediatrics, University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH 45267, USA; Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 2021, Cincinnati, OH 45229, USA. Electronic address: [email protected].

PMID: 36344070
DOI: 10.1016/j.ccm.2022.06.005

Abstract

As routine care in cystic fibrosis (CF) becomes increasingly personalized, new opportunities to further focus care on the individual have emerged. These opportunities are increasingly filled through research in tools aiding drug selection, drug monitoring and titration, disease-relevant biomarkers, and evaluation of therapeutic benefits. Herein, we will discuss such research tools presently being translated into the clinic to improve the personalization of care in CF.

Keywords: CFTR; CFTR modulator; Cystic fibrosis; Personalized medicine.

Publication types

Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Biomarkers
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis Transmembrane Conductance Regulator / therapeutic use
Cystic Fibrosis* / drug therapy
Humans
Mutation
Precision Medicine

Substances

Cystic Fibrosis Transmembrane Conductance Regulator
Biomarkers